• Something wrong with this record ?

Impact of dopamine and cognitive impairment on neural reactivity to facial emotion in Parkinson's disease

R. Dan, F. Růžička, O. Bezdicek, J. Roth, E. Růžička, J. Vymazal, G. Goelman, R. Jech,

. 2019 ; 29 (11) : 1258-1272. [pub] 20191010

Language English Country Netherlands

Document type Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20025530

Emotional and cognitive impairments in Parkinson's disease (PD) are prevalent, hamper interpersonal relations and reduce quality of life. It is however unclear to what extent these domains interplay in PD-related deficits and how they are influenced by dopaminergic availability. This study examined the effect of cognitive impairment and dopaminergic medication on neural and behavioral mechanisms of facial emotion recognition in PD patients. PD patients on and off dopaminergic medication and matched healthy controls underwent an emotional face matching task during functional MRI. In addition, a comprehensive neuropsychological evaluation of cognitive function was conducted. Increased BOLD response to emotional faces was found in the visual cortex of PD patients relative to controls irrespective of cognitive function and medication status. Administration of dopaminergic medication in PD patients resulted in restored behavioral accuracy for emotional faces relative to controls and decreased retrosplenial cortex BOLD response to emotion relative to off-medication state. Furthermore, cognitive impairment in PD patients was associated with reduced behavioral accuracy for non-emotional stimuli and predicted BOLD response to emotion in the anterior and posterior cingulate cortices, depending on medication status. Findings of aberrant visual and retrosplenial BOLD response to emotion are suggested to stem from altered attentional and/or emotion-driven modulation from subcortical and higher cortical regions. Our results indicate neural disruptions and behavioral deficits in emotion processing in PD patients that are dependent on dopaminergic availability and independent of cognitive function. Our findings highlight the importance of dopaminergic treatment not only for the motor symptoms but also the emotional disturbances in PD.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025530
003      
CZ-PrNML
005      
20201222160249.0
007      
ta
008      
201125s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euroneuro.2019.09.003 $2 doi
035    __
$a (PubMed)31607424
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Dan, Rotem $u Edmond and Lily Safra Center for Brain Sciences (ELSC), The Hebrew University of Jerusalem, Jerusalem, Israel; Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
245    10
$a Impact of dopamine and cognitive impairment on neural reactivity to facial emotion in Parkinson's disease / $c R. Dan, F. Růžička, O. Bezdicek, J. Roth, E. Růžička, J. Vymazal, G. Goelman, R. Jech,
520    9_
$a Emotional and cognitive impairments in Parkinson's disease (PD) are prevalent, hamper interpersonal relations and reduce quality of life. It is however unclear to what extent these domains interplay in PD-related deficits and how they are influenced by dopaminergic availability. This study examined the effect of cognitive impairment and dopaminergic medication on neural and behavioral mechanisms of facial emotion recognition in PD patients. PD patients on and off dopaminergic medication and matched healthy controls underwent an emotional face matching task during functional MRI. In addition, a comprehensive neuropsychological evaluation of cognitive function was conducted. Increased BOLD response to emotional faces was found in the visual cortex of PD patients relative to controls irrespective of cognitive function and medication status. Administration of dopaminergic medication in PD patients resulted in restored behavioral accuracy for emotional faces relative to controls and decreased retrosplenial cortex BOLD response to emotion relative to off-medication state. Furthermore, cognitive impairment in PD patients was associated with reduced behavioral accuracy for non-emotional stimuli and predicted BOLD response to emotion in the anterior and posterior cingulate cortices, depending on medication status. Findings of aberrant visual and retrosplenial BOLD response to emotion are suggested to stem from altered attentional and/or emotion-driven modulation from subcortical and higher cortical regions. Our results indicate neural disruptions and behavioral deficits in emotion processing in PD patients that are dependent on dopaminergic availability and independent of cognitive function. Our findings highlight the importance of dopaminergic treatment not only for the motor symptoms but also the emotional disturbances in PD.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kognitivní dysfunkce $x komplikace $x farmakoterapie $x patofyziologie $7 D060825
650    _2
$a agonisté dopaminu $x farmakologie $x terapeutické užití $7 D018491
650    _2
$a emoce $x účinky léků $x fyziologie $7 D004644
650    12
$a výraz obličeje $7 D005149
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a funkční zobrazování neurálních procesů $7 D059907
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neurozobrazování $7 D059906
650    _2
$a neuropsychologické testy $7 D009483
650    _2
$a Parkinsonova nemoc $x komplikace $x farmakoterapie $x patofyziologie $7 D010300
650    _2
$a zrakové korové centrum $x účinky léků $x fyziologie $7 D014793
655    _2
$a klinické zkoušky kontrolované $7 D018848
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Růžička, Filip $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czechia; Department of Radiology, Na Homolce Hospital, Prague, Czechia.
700    1_
$a Bezdicek, Ondrej $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czechia.
700    1_
$a Roth, Jan $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czechia.
700    1_
$a Růžička, Evžen $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czechia.
700    1_
$a Vymazal, Josef $u Department of Radiology, Na Homolce Hospital, Prague, Czechia.
700    1_
$a Goelman, Gadi $u Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: gadig@hadassah.org.il.
700    1_
$a Jech, Robert $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czechia; Department of Radiology, Na Homolce Hospital, Prague, Czechia.
773    0_
$w MED00001656 $t European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology $x 1873-7862 $g Roč. 29, č. 11 (2019), s. 1258-1272
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31607424 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160244 $b ABA008
999    __
$a ok $b bmc $g 1599675 $s 1116216
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 29 $c 11 $d 1258-1272 $e 20191010 $i 1873-7862 $m European neuropsychopharmacology $n Eur Neuropsychopharmacol $x MED00001656
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options